# ImpriMed, Inc.

- **Section**: news
- **Answer**: ImpriMed, Inc.: 18 headlines on record, 5 headlines in the last 90 days. Its story counts 4 milestones.
- **As of**: 2026-11-17
- **Cite**: ImpriMed, Inc., News. Alion, Nov 17, 2026. https://alion.io/company/imprimedicine/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 2676315
- **Name**: ImpriMed, Inc.
- **Domain**: imprimedicine.com
- **Url**: <https://alion.io/company/imprimedicine>

## Figures

- Label: Headlines; Value: 18
- Label: In 90 days; Value: 5
- Label: Milestones; Value: 4

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 16
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 4

## News

- [From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology Pharmacy Times](https://pharmacytimes.com/view/from-dogs-to-humans-ai-powered-drug-response-prediction-technology-demonstrates-improved-clinical-outcomes-in-oncology) — Date: 2026-09-29; Kind: News; Source: Pharmacy Times
- [Comparative Oncology: Advances in Cancer Care from Pets to Humans Pharmacy Times](https://pharmacytimes.com/view/comparative-oncology-advances-in-cancer-care-from-pets-to-humans) — Date: 2026-09-29; Kind: News; Source: Pharmacy Times
- [New AI service offers personalized drug response predictions for canine patients with cancer](https://dvm360.com/view/new-ai-service-offers-personalized-drug-response-predictions-for-canine-patients-with-cancer) — Date: 2026-09-29; Kind: News; Source: dvm360
- [Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma](https://dvm360.com/view/flow-cytometry-and-clonality-evaluation-are-effective-for-characterizing-feline-lymphoma) — Date: 2026-09-29; Kind: News; Source: dvm360
- [NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed](https://tmcnet.com/usubmit/2026/09/18/10448330.htm) — Date: 2026-09-17; Kind: News; Source: tmcnet.com
- [ImpriMed CEO Dr. Sungwon Lim Invited to National Cancer Institute Panel on Commercializing Functional Precision Medicine](https://businesswire.com/news/home/20260701788991/en/ImpriMed-CEO-Dr.-Sungwon-Lim-Invited-to-National-Cancer-Institute-Panel-on-Commercializing-Functional-Precision-Medicine) — Date: 2026-07-01; Kind: Press release; Source: businesswire
- [ImpriMed Unveils Cancer Treatment Prediction Technology at EHA-SfPM Meeting, Expands AI-Driven Precision Medicine Services from Pets to Humans](https://businesswire.com/news/home/20240923577061/en/ImpriMed-Unveils-Cancer-Treatment-Prediction-Technology-at-EHA-SfPM-Meeting-Expands-AI-Driven-Precision-Medicine-Services-from-Pets-to-Humans/) — Date: 2024-09-22; Kind: Press release; Source: businesswire.com
- [ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market](https://pulse2.com/imprimed-sungwon-lim-profile/) — Date: 2024-06-12; Kind: News; Source: Pulse 2.0
- [How AI Can Help Treat (and Cure) Your Dog's Cancer](https://thedailybeast.com/how-ai-from-imprimed-can-help-treat-and-cure-your-dogs-cancer/) — Date: 2024-01-29; Kind: News; Source: The Daily Beast
- [ImpriMed: Precision Medicine Company Secures $23 Million To Improve Cancer Treatment](https://pulse2.com/imprimed-23-million-funding/) — Date: 2023-12-21; Kind: News; Source: Pulse 2.0
- [Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology](https://techcrunch.com/2023/12/19/dog-cancer-treatment-imprimed-aims-to-expand-its-ai-technology-into-human-oncology/) — Date: 2023-12-19; Kind: News; Source: TechCrunch
- [ImpriMed Raises $23 Million Series A Round to Expand its Revolutionary AI-Powered Cancer Treatment Technology](https://businesswire.com/news/home/20231219536657/en/ImpriMed-Raises-23-Million-Series-A-Round-to-Expand-its-Revolutionary-AI-Powered-Cancer-Treatment-Technology/) — Date: 2023-12-18; Kind: Press release; Source: businesswire.com
- [ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma](https://finance.yahoo.com/news/imprimed-launches-chemo-response-prediction-120000758.html) — Date: 2021-05-24; Kind: News; Source: YahooFinance
- [How ImpriMed Turned Nine Years in Veterinary Oncology Into a Human Blood Cancer Business](https://synbiobeta.com/read/how-imprimed-turned-nine-years-in-veterinary-oncology-into-a-human-blood-cancer-business) — Kind: News; Source: synbiobeta.com
- [One moment, please...](https://veterinary-practice.com/2024/cell-sizing-method-for-feline-lymphoma-characterisation) — Kind: News; Source: veterinary-practice.com
- [Client Challenge](https://link.springer.com/article/10.1007/s12257-026-00289-z) — Kind: News; Source: link.springer.com

## Story

- [Launched ImpriMed Unveils Cancer Treatment Prediction Technology at EHA-SfPM Meeting, Expands AI-Driven Precision Medicine Services from Pets to Humans · businesswire.com](https://businesswire.com/news/home/20240923577061/en/ImpriMed-Unveils-Cancer-Treatment-Prediction-Technology-at-EHA-SfPM-Meeting-Expands-AI-Driven-Precision-Medicine-Services-from-Pets-to-Humans/)
- [Raised a round Series A $23M](https://businesswire.com/news/home/20231219536657/en/ImpriMed-Raises-23-Million-Series-A-Round-to-Expand-its-Revolutionary-AI-Powered-Cancer-Treatment-Technology/)
- [Launched ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma · YahooFinance](https://finance.yahoo.com/news/imprimed-launches-chemo-response-prediction-120000758.html)
- **Founded**

---
[Page](https://alion.io/company/imprimedicine/news) · [JSON](https://alion.io/company/imprimedicine/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
